Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Amortization of Deferred Charges (2016 - 2025)

Historic Amortization of Deferred Charges for Ironwood Pharmaceuticals (IRWD) over the last 13 years, with Q3 2025 value amounting to $418000.0.

  • Ironwood Pharmaceuticals' Amortization of Deferred Charges rose 1942.86% to $418000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year decrease of 1979.77%. This contributed to the annual value of $1.9 million for FY2024, which is 757.28% down from last year.
  • Ironwood Pharmaceuticals' Amortization of Deferred Charges amounted to $418000.0 in Q3 2025, which was up 1942.86% from $416000.0 recorded in Q2 2025.
  • Ironwood Pharmaceuticals' Amortization of Deferred Charges' 5-year high stood at $6.1 million during Q4 2021, with a 5-year trough of $350000.0 in Q3 2024.
  • Moreover, its 5-year median value for Amortization of Deferred Charges was $516000.0 (2022), whereas its average is $1.6 million.
  • As far as peak fluctuations go, Ironwood Pharmaceuticals' Amortization of Deferred Charges tumbled by 9349.38% in 2022, and later soared by 4675.0% in 2023.
  • Quarter analysis of 5 years shows Ironwood Pharmaceuticals' Amortization of Deferred Charges stood at $6.1 million in 2021, then tumbled by 93.49% to $400000.0 in 2022, then soared by 46.75% to $587000.0 in 2023, then decreased by 29.3% to $415000.0 in 2024, then increased by 0.72% to $418000.0 in 2025.
  • Its last three reported values are $418000.0 in Q3 2025, $416000.0 for Q2 2025, and $416000.0 during Q1 2025.